Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

How have inflammatory bowel disease treatments changed after the introduction of biologics?

Researchers compared changes in inflammatory bowel disease treatment strategies before and after the introduction of biologics in Japan.

24 Aug 2023

Novel antibody could be safer and more effective than existing treatments for autoimmune diseases

Researchers have shown that a novel antibody generated to target an 'essential amino acid sequence' of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).

14 Aug 2023

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Researchers examined the association between antidrug antibodies and the response to treatments for rheumatoid arthritis.

17 Jul 2023

Two anti-inflammatory drugs reduce deaths in severe COVID-19 patients

Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis. William G. Powderly, MD, (right) who led the large clinical trial, discusses patient conditions with Maanasi Samant, MD, in the intensive care unit at Barnes-Jewish Hospital, one of the major trial sites, during the COVID-19 pandemic.

10 Jul 2023

Clinical trial findings may be a game changer in the treatment of pediatric Crohn's disease

Crohn's disease is a lifelong inflammatory bowel disease (IBD) that is characterized by swelling in the lining of the digestive tract, causing severe diarrhea, abdominal pain, and rectal bleeding.

3 Apr 2023

Case report on Nocardia pseudobrasiliensis and SARS-CoV-2 concomitant infection

In a recent case report published in the U.S. Centers for Disease Control and Prevention’s (CDC) journal Emerging Infectious Diseases, researchers reported a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Nocardia pseudobrasiliensis concomitant infection.

27 Mar 2023

Can the gut microbiota and metabolome explain variation in anti-SARS-CoV-2 vaccination responses in immunosuppressed IBD patients?

Researchers explored the connection between the metabolic function of the gut microbiota, its composition, and immune response to SARS-CoV-2 vaccination in IBD patients.

27 Feb 2023

Study shows how arthritis affects people's working lives

The typical person living with arthritis in the UK is 20% less likely to be in work than their equivalent without the condition, new research shows.

30 Jan 2023

Study establishes a feasible combination therapeutic strategy for ulcerative colitis

Despite recent advancements in our knowledge of the pathogenic mechanisms of ulcerative colitis, there is still a considerable unmet medical need for the treatment of ulcerative colitis.

29 Sep 2022

New treatment guidelines published for anorectal abscess, anal fistula, and rectovaginal fistula

The American Society of Colon and Rectal Surgeons has issued updated guidelines for physicians, published in Diseases of the Colon & Rectum, about how to treat problems of the anus and rectum called anorectal abscess, anal fistula, and rectovaginal fistula.

22 Jul 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Researchers investigated whether COVID-19 vaccination effectively protected adolescents in the United States from multisystem inflammatory syndrome (MIS).

2 Jun 2022

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

In a recent study posted to the Research Square* preprint server, researchers assessed whether disturbances in the gut microbiota weaken the serological response to the coronavirus disease 2019 (COVID-19) vaccine in inflammatory bowel disease (IBD) patients.

25 May 2022

New insight into lymphoid cell maturity could pave the way for more effective IBD treatments

A research group at Karolinska Institutet in Sweden has analyzed how certain immune cells known as innate lymphoid cells (ILCs) develop into mature cells that play a part in inflammatory bowel disease (IBD).

15 Apr 2022

Heart complications uncommon for children and young adults after SARS-CoV-2 infection

Heart complications are uncommon, yet treatable for children and young adults after COVID-19 disease or SARS-CoV-2 infection, according to a new scientific statement from the American Heart Association that details what has been learned about how to treat, manage and even prevent cardiovascular complications from the SARS-CoV-2 virus in youth.

12 Apr 2022

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Researchers estimated the immunogenicity of SARS-CoV-2 vaccination in a Belgian cohort of patients with ankylosing spondylitis.

7 Mar 2022

Trial identifies a drug that may benefit some patients hospitalized with COVID-19 pneumonia

A proof-of-concept trial led by the Universities of Birmingham and University Hospitals Birmingham NHS Foundation Trust has identified a drug that may offer benefit some patients hospitalized with COVID-19 pneumonia.

18 Dec 2021

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors - a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions - generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

A recent study evaluates the immune responses elicited by COVID-19 vaccines in infliximab- or vedolizumab-treated IBD patients.

15 Nov 2021